Supply of primaquine (as phosphate)(PRIMACIN) 7.5 mg tablet tube by Boucher & Muir Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted in 1989, governs the regulation of therapeutic goods in Australia, ensuring their quality, safety, and efficacy. This legislation was introduced to address the need for a comprehensive regulatory framework to manage the provision of therapeutic goods, including medicines, medical devices, and blood products, thereby protecting public health. On February 20, 2013, the delegate of the Secretary of the Department of Health and Ageing provided a consent under the Act, allowing Boucher & Muir Pty Ltd to supply primaquine (as phosphate) 7.5 mg tablets in packaging that does not meet child-resistant packaging requirements, subject to specific conditions. This consent is aimed at balancing the therapeutic needs of patients with the imperative to maintain stringent safety standards, as evidenced by the requirement for accompanying patient information and communications with healthcare professionals.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation of therapeutic goods, including medicines, within Australia. The Act governs the quality, efficacy, and safety of therapeutic goods, ensuring that they meet specific standards before being made available to the public. Section 14 and 14A of the Act provide mechanisms for granting specific consents for therapeutic goods that do not fully comply with established regulations, such as packaging requirements, under certain conditions. The Act applies to entities involved in the supply of therapeutic goods, including pharmaceutical companies and other businesses that manufacture, supply, or distribute these products. The geographic reach of the Act is national, extending across all states and territories in Australia. While the Act generally applies to all therapeutic goods, it includes provisions for exemptions and consents where strict compliance with certain regulations is not feasible, provided specific conditions are met. Subordinate instruments, such as therapeutic goods orders, further detail the specific requirements and standards that therapeutic goods must meet.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) sets out provisions for the regulation of therapeutic goods in Australia. Section 14 of the Act allows for the delegate of the Secretary of the Department of Health and Ageing to provide consent for the supply of therapeutic goods that do not conform to specific regulations or standards, provided that certain conditions are met. In this case, Section 14A Notice was issued on February 20, 2013, allowing Boucher & Muir Pty Ltd (the Company) to supply the product primaquine (as phosphate) (PRIMACIN) 7.5 mg tablet tube [Aust R 63856] in packaging that does not comply with paragraphs 6(1)(a) and 9 of Therapeutic Goods Order (TGO) 80 (Child Resistant Packaging requirements for Medicines). The Act imposes several obligations on the parties involved. Firstly, the consent to supply the non-compliant product is contingent on the product being supplied in its current packaging and without any other changes. This ensures that the product supplied remains consistent with the conditions under which consent was granted. Secondly, the Company must provide a Dear Healthcare Professional letter with each supply of the product, which was included in the email correspondence of February 20, 2013. Additionally, every patient receiving the product must be given a copy of the patient handout, as specified in the email correspondence of February 19, 2013. Failure to adhere to the conditions outlined in the Section 14A Notice can result in civil or criminal penalties. The Act does not specify the exact penalties for breaches, but it is important to note that non-compliance with therapeutic goods regulations can lead to serious consequences, including fines and potential criminal charges. The severity of the penalties may depend on the nature and extent of the breach, as well as any harm caused by the non-compliant supply. In cases where the breach involves significant risks to public health and safety, the penalties could be particularly severe.